



(19) REPUBLIKA HRVATSKA  
DRŽAVNI ZAVOD ZA  
INTELEKTUALNO VLASNIŠTVO



(10) Identifikator  
dokumenta:

HR P20130971 T1

HR P20130971 T1

(12) **PRIJEVOD PATENTNIH ZAHTJEVA  
EUROPSKOG PATENTA**

(51) MKP:

**C07D 417/14 (2006.01)**  
**C07D 401/12 (2006.01)**  
**C07D 401/14 (2006.01)**  
**C07D 403/14 (2006.01)**  
**C07D 409/14 (2006.01)**  
**C07D 413/14 (2006.01)**  
**C07D 417/12 (2006.01)**

(46) Datum objave prijevoda patentnih zahtjeva: 08.11.2013.

(21) Broj predmeta: P20130971T

(22) Datum podnošenja zahtjeva u HR: 14.10.2013.

(86) Broj međunarodne prijave: PCT/CA2005000208  
Datum podnošenja međunarodne prijave: 18.02.2005.

(96) Broj europske prijave patenta: EP 05714457.8  
Datum podnošenja europske prijave patenta: 18.02.2005.

(87) Broj međunarodne objave: WO 2005080388  
Datum međunarodne objave: 01.09.2005.

(97) Broj objave europske prijave patenta: EP 1718608 A1  
Datum objave europske prijave patenta: 08.11.2006.

(97) Broj objave europskog patenta: EP 1718608 B1  
Datum objave europskog patenta: 17.07.2013.

(31) Broj prve prijave: 546213 P

(32) Datum podnošenja prve prijave: 20.02.2004.

(33) Država ili organizacija podnošenja prve prijave: US

(73) Nositelj patenta:

**Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216  
Ingelheim am Rhein, DE**

(72) Izumitelji:

**Youla S. Tsantrizos, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Catherine Chabot, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Pierre Beaulieu, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Christian Brochu, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Martin Poirier, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Timothy A. Stammers, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
**Bounkham Thavonekham, 2100 Cunard Street, Laval, Québec H7S 2G5,  
CA**

(74) Zastupnik:

**Jean Rancourt, 2100 Cunard Street, Laval, Québec H7S 2G5, CA**  
CPZ - CENTAR ZA PATENTE d.o.o., 10000 Zagreb, HR


(54) Naziv izuma:

**INHIBITORI VIRUSNE POLIMERAZE**


HR P20130971 T1

**PATENTNI ZAHTJEVI**


- 5 1. Spoj, **naznačen time, da** je odabran od sljedećih:




;










;




;




;







;




;




;




;




;




;




;




1




2




3










4

















5










6




















































i







ili njegova sol ili njegov ester.

- 5 2. Spoj prema zahtjevu 1, **naznačen time, da** je odabran od sljedećih:




















ili njegova farmaceutski prihvatljiva sol.


3. Spoj prema zahtjevu 1, **naznačen time, da** je odabran od sljedećih:

















5








ili njegova farmaceutski prihvatljiva sol.




4. Spoj prema zahtjevu 1, **naznačen time, da** je odabran od sljedećih:






















ili njegova farmaceutski prihvatljiva sol.


5. Spoj prema zahtjevu 1, **naznačen time, da** je odabran od sljedećih:






ili njegova farmaceutski prihvatljiva sol.

6. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:




ili njegova farmaceutski prihvatljiva sol.

7. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:




5 ili njegova farmaceutski prihvatljiva sol.

8. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:



ili njegova farmaceutski prihvatljiva sol.


9. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:



10


ili njegova farmaceutski prihvatljiva sol.

10. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:



ili njegova farmaceutski prihvatljiva sol.

- 15 11. Spoj prema zahtjevu 1, **naznačen time**, da ima sljedeću strukturu:



ili njegova farmaceutski prihvatljiva sol.

12. Farmaceutski sastav, **naznačen time**, da služi za liječenje ili prevenciju HCV-infekcije, te da sadrži učinkovitu količinu spoja prema jednom ili više od zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli ili njegovog estera, kao i farmaceutski prihvatljiv nosač.
13. Sastav prema zahtjevu 12, **naznačen time**, da nadalje sadrži terapeutsku učinkovitu količinu jednoga ili više antivirusnih sredstava.
14. Sastav prema zahtjevu 13, **naznačen time**, da je spomenuto antivirusno sredstvo odabrano od ribavirina i amantadina.
15. Sastav prema zahtjevu 13, **naznačen time**, da antivirusno sredstvo je jedno sljedeće anti-HCV-sredstvo.
16. Farmaceutski sastav prema zahtjevu 15, **naznačen time**, da je sljedeće anti-HCV-sredstvo jedno imunomodulacijsko sredstvo odabrano od  $\alpha$ -,  $\beta$ -,  $\delta$ - $\gamma$ -,  $\tau$ - i  $\omega$ -interferona te od njihovih pegiliranih oblika.
17. Sastav prema zahtjevu 15, **naznačen time**, da sljedeće anti-HCV-sredstvo je dodatni inhibitor HCV-polimeraze.



18. Sastav prema zahtjevu 15, **naznačen time, da** sljedeće anti-HCV-sredstvo je inhibitor HCV NS3-proteaze.
19. Sastav prema zahtjevu 15, **naznačen time, da** sljedeće anti-HCV-sredstvo je inhibitor nekog drugog cilja u životnom ciklusu HCV-a.
- 5 20. Sastav prema zahtjevu 19, **naznačen time, da** spomenuti inhibitor nekog drugog cilja u životnom ciklusu HCV-a je odabran od sredstva koje inhibira cilj odabran između HCV-helikaze, HCV NS2/3-proteaze i HCV IRES-a, i sredstva koje interferira s djelovanjem NS5A-proteina.
21. Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, **naznačen time, da** se upotrebljava kao inhibitor HCV-polimeraze.
- 10 22. Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, **naznačen time, da** se upotrebljava kao inhibitor RNK-ovisne RNK-polimeraze djelovanja enzima NS5B, koja je kodirana HCV-om.
23. Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, **naznačen time, da** se upotrebljava kao inhibitor HCV-replikacije.
- 15 24. Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, **naznačen time, da** se upotrebljava za liječenje ili prevenciju HCV-infekcije kod sisavaca.
25. Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, **naznačen time, da** se upotrebljava za liječenje ili prevenciju HCV-infekcije kod sisavaca, u kombinaciji s dodatnim antivirusnim sredstvom.
- 20 26. Postupak in-vitro inhibicije RNK-ovisne RNK-polimeraze djelovanja enzima NS5B, koja je kodirana HCV-om, **naznačen time, da** obuhvaća izlaganje enzima NS5B učinkovitoj količini spoja prema jednom ili više od zahtjeva 1 do 11 pod uvjetima u kojima se inhibira RNK-ovisna RNK-polimeraza djelovanja enzima NS5B.
27. Postupak in-vitro inhibicije HCV-replikacije, **naznačen time, da** obuhvaća izlaganje HCV-inficirane stanice učinkovitoj količini spoja prema jednom ili više od zahtjeva 1 do 11 pod uvjetima u kojima se inhibira HCV-replikacija.
- 25 28. Farmaceutski prihvatljiva sol ili ester od spoja prema jednom ili više od zahtjeva 1 do 11, ili njegov sastav, **naznačen(a) time, da** se upotrebljava u postupku liječenja ili prevencije HCV-infekcije kod sisavaca, koji obuhvaća primjenu na sisavcu učinkovite količine farmaceutski prihvatljive soli ili estera, ili sastava.
29. Farmaceutski prihvatljiva sol ili ester od spoja prema jednom ili više od zahtjeva 1 do 11, ili njegov sastav, **naznačen(a) time, da** se upotrebljava u postupku liječenja ili prevencije HCV-infekcije kod sisavaca, koji obuhvaća primjenu na sisavcu učinkovite količine farmaceutski prihvatljive soli ili estera, ili sastava, u kombinaciji s dodatnim antivirusnim sredstvom.
- 30 30. Uporaba spoja prema jednom ili više od zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli ili njegovog estera, ili njegovog sastava, **naznačena time, da** je za proizvodnju lijeka za liječenje i/ili prevenciju virusne Flavivirid-infekcije.
- 35 31. Uporaba spoja prema jednom ili više od zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli ili njegovog estera, ili njegovog sastava, **naznačena time, da** je za proizvodnju lijeka za liječenje i/ili prevenciju HCV-infekcije.
32. Predmet proizvodnje, **naznačen time, da** obuhvaća sastav učinkovit za liječenje HCV-infekcije ili za inhibiciju NS5B-polimeraze od HCV-a te pakirni materijal koji sadrži etiketu koja naznačava da se sastav može upotrebljavati za liječenje infekcije od virusnog hepatitisa C, pri čemu spomenuti sastav obuhvaća spoj prema jednom ili više od  
40 zahtjeva 1 do 11 ili njegovu farmaceutski prihvatljivu sol ili njegov ester.